Imaging data will be acquired from approximately 24 clinical sites in Europe and Asia, which is expected to enroll 200 patients. MEDIAN will provide clinical site qualification and training, image data collection, quality control, centralized data storage, and Independent Central Review (ICR) services using its Lesion Management Solutions (LMS) software. LMS is a suite of software modules for the review of images and quantitative assessment of response to therapy in trials.
"We are proud of this new project award and enthusiastic about working with both our CRO strategic partner and the specialty pharmaceutical company sponsor on this Phase III study," said Fredrik Brag, chairman and chief executive officer of MEDIAN Technologies. "This award further reinforces the value of our alliance and strengthens our commercial positioning."